KR101872746B1 - 질병 치료용 제제 - Google Patents

질병 치료용 제제 Download PDF

Info

Publication number
KR101872746B1
KR101872746B1 KR1020127016947A KR20127016947A KR101872746B1 KR 101872746 B1 KR101872746 B1 KR 101872746B1 KR 1020127016947 A KR1020127016947 A KR 1020127016947A KR 20127016947 A KR20127016947 A KR 20127016947A KR 101872746 B1 KR101872746 B1 KR 101872746B1
Authority
KR
South Korea
Prior art keywords
amino acid
acid position
antibody
delete delete
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127016947A
Other languages
English (en)
Korean (ko)
Other versions
KR20120102733A (ko
Inventor
프랑크 오스터로스
크리스토프 우헤렉
크리스토프 브루에쉐어
벤야민 다엘켄
안드레 잉글링
찬탈 주베르
니클라스 첼로스
홀거 월마이어
커스틴 볼프
그레거 슐츠
Original Assignee
바이오테스트 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오테스트 아게 filed Critical 바이오테스트 아게
Publication of KR20120102733A publication Critical patent/KR20120102733A/ko
Application granted granted Critical
Publication of KR101872746B1 publication Critical patent/KR101872746B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020127016947A 2009-11-30 2010-11-30 질병 치료용 제제 Expired - Fee Related KR101872746B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0920944.6 2009-11-30
GBGB0920944.6A GB0920944D0 (en) 2009-11-30 2009-11-30 Agents for treating disease
PCT/EP2010/068579 WO2011064407A1 (en) 2009-11-30 2010-11-30 Agents for treating disease

Publications (2)

Publication Number Publication Date
KR20120102733A KR20120102733A (ko) 2012-09-18
KR101872746B1 true KR101872746B1 (ko) 2018-06-29

Family

ID=41572903

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127016947A Expired - Fee Related KR101872746B1 (ko) 2009-11-30 2010-11-30 질병 치료용 제제

Country Status (17)

Country Link
US (1) US9995733B2 (enExample)
EP (1) EP2470902B1 (enExample)
JP (1) JP5959438B2 (enExample)
KR (1) KR101872746B1 (enExample)
CN (1) CN102687010B (enExample)
AU (1) AU2010323045B2 (enExample)
BR (1) BR112012012911A8 (enExample)
CA (1) CA2781836A1 (enExample)
ES (1) ES2643640T3 (enExample)
GB (1) GB0920944D0 (enExample)
IL (1) IL219956B (enExample)
MX (1) MX347247B (enExample)
NZ (1) NZ600889A (enExample)
RU (1) RU2598719C2 (enExample)
SG (2) SG181117A1 (enExample)
WO (1) WO2011064407A1 (enExample)
ZA (1) ZA201204845B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
EP2471543A1 (en) * 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
US20170232084A1 (en) 2013-04-26 2017-08-17 Enzo Biochem Inc. Immune modulation for the treatment of age-related macular degeneration
US20140322188A1 (en) 2013-04-26 2014-10-30 Enzo Biochem, Inc. Tolerizing treatments for autoimmune disease
GB201413899D0 (en) 2014-08-06 2014-09-17 Johnson Matthey Plc Catalyst and use therof
CR20170482A (es) * 2015-04-24 2018-03-07 Viiv Healthcare Uk No 5 Ltd Polipéptidos dirigidos a la fusión de vih
US20180126021A1 (en) * 2016-11-04 2018-05-10 Covidien Lp Sterilization system and method
GB202017681D0 (en) 2020-11-09 2020-12-23 T Balance Therapeutics Gmbh Anti-CD4 antibody or fragment thereof for medical use
AU2022492449A1 (en) * 2022-12-29 2025-07-10 Chang Gung Memorial Hospital, Linkou Antibodies specific to transmembrane and coiled-coil domain family 3 and uses thereof
GB202401501D0 (en) 2024-02-05 2024-03-20 T Balance Therapeutics Gmbh Medical use of regulatory t cell activator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009112502A1 (en) * 2008-03-13 2009-09-17 Biotest Ag Agent for treating disease

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT90657B (pt) 1988-05-27 1995-03-01 Ortho Pharma Corp Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
JPH0768273B2 (ja) * 1988-12-02 1995-07-26 カルピス食品工業株式会社 抗ｈｉｖペプチド
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990013562A1 (en) 1989-05-02 1990-11-15 Genelabs Incorporated Chemically modified cd4 peptide fragments having anti-retroviral properties
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
ATE153536T1 (de) 1990-11-27 1997-06-15 Biogen Inc Hiv-induzierte synzytien blockierender anti-cd-4- antikörper
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
IL101769A (en) 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
JP3616091B2 (ja) 1992-10-08 2005-02-02 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
DK0614984T4 (da) 1993-03-05 2010-12-20 Bayer Healthcare Llc Humane monoklonale anti-TNF-alfa-antistoffer
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
JPH09510952A (ja) 1993-10-06 1997-11-04 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
US20020068057A1 (en) 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
PT840618E (pt) 1995-05-18 2003-08-29 Ortho Mcneil Pharm Inc Inducao de tolerancia imunologica atraves de anticorpos anti-cd4 nao-depletores
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US20010056066A1 (en) 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
AU4563197A (en) 1996-10-01 1998-04-24 Celltech Therapeutics Limited Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
DE19722888A1 (de) 1997-05-28 1998-12-03 Thomas Prof Dr Huenig Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
WO2000074718A1 (en) 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
AU6941000A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use
US7304127B2 (en) 1999-08-27 2007-12-04 United States Of America As Represented By The Secretary, Department Of Health And Human Services Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
AU2001275186A1 (en) 2000-06-02 2001-12-17 Nicole Kirchhof Immunotherapeutic method to prevent islet cell rejection
CN1592645A (zh) 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
DE10050935A1 (de) 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
EP2314293B1 (en) 2001-01-16 2017-01-04 Vascular Therapies, LLC Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases
EP1372721A4 (en) 2001-03-07 2008-04-02 Childrens Medical Center METHOD FOR SCREENING PEPTIDE DISPLAY LIBRARIES WITH A MINIMUM DISPLAY
EP1241249A1 (en) 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
AU2002316855B2 (en) 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
DE60238533D1 (de) 2001-06-14 2011-01-20 Cambridge Entpr Ltd Nicht-depletierender Antikörper TRX-1 gegen CD4 und dessen Verwendungen
GB2376466A (en) 2001-06-14 2002-12-18 Mark Frewin TRX1 antibody
US7541443B2 (en) 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
EP1451224B1 (de) 2001-12-04 2012-08-15 TheraMAB LLC Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie
DE10212108A1 (de) 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
HRP20090325T1 (en) 2003-04-09 2009-07-31 Genentech Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
GB0314461D0 (en) 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
EP1600164A3 (de) 2003-09-22 2006-05-17 TeGenero AG Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
BRPI0512017A (pt) 2004-06-22 2008-02-06 Tolerrx Inc dosagem otimizada com anticorpos anti-cd4 para indução de toleráncia em primatas
CN101010342A (zh) 2004-07-02 2007-08-01 健泰科生物技术公司 用于治疗非何杰金淋巴瘤的组合物和方法
EP1797882A4 (en) 2004-09-29 2009-11-18 Kowa Co PREVENTIVE AND / OR THERAPEUTIC MEDICAMENT FOR RHEUMATOID ARTHRITIS
ES2437571T3 (es) 2004-11-11 2014-01-13 Theramab Llc Anticuerpos anti-CD28 superagonistas
WO2006055077A2 (en) 2004-11-12 2006-05-26 The University Of North Carolina At Charlotte Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
JP4730733B2 (ja) 2005-05-02 2011-07-20 国立大学法人京都大学 ４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
SG163615A1 (en) 2005-07-11 2010-08-30 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
DE602006019977D1 (de) 2005-08-18 2011-03-17 Genmab As Therapie mit anti-cd4-antikörpern und bestrahlung
WO2007031875A2 (en) 2005-08-26 2007-03-22 Glycart Biotechnology Ag Modified antigen binding molecules with altered cell signaling activity
WO2007130697A2 (en) * 2006-01-05 2007-11-15 Genentech, Inc. Anti-ephb4 antibodies and methods using same
KR20080112300A (ko) 2006-03-16 2008-12-24 제넨테크, 인크. Ｃｄ4 항체를 사용하여 루푸스를 치료하는 방법
WO2007111661A2 (en) 2006-03-20 2007-10-04 Xoma Technology Ltd. Human antibodies specific for gastrin materials and methods
US20090208471A1 (en) 2006-04-07 2009-08-20 Yun Theodore J Isolation and Use of Human Regulatory T Cells
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
WO2007135684A2 (en) * 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Method of treatment of anti-cd4 autoimmunity
ES2593789T3 (es) 2007-02-01 2016-12-13 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Activación específica de una célula T reguladora y su uso para el tratamiento del asma, enfermedades alérgicas, enfermedades autoinmunes, rechazo de injertos y para la inducción de tolerancia
WO2008134046A1 (en) 2007-04-27 2008-11-06 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
CA2718184A1 (en) 2008-03-13 2009-10-08 Biotest Ag Agent for treating disease
KR20100135807A (ko) 2008-03-13 2010-12-27 바이오테스트 아게 질병 치료제
EP2101173A1 (en) 2008-03-14 2009-09-16 Vivalis In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
ES2335381B1 (es) 2008-09-24 2011-02-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
RU2531548C2 (ru) 2008-09-29 2014-10-20 Биотест Аг Композиция для лечения заболевания
ES2351456B1 (es) 2009-06-24 2011-11-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b
JP5399219B2 (ja) 2009-11-24 2014-01-29 株式会社ケイティーバイオ 関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
WO2011158798A1 (ja) 2010-06-14 2011-12-22 国立大学法人山口大学 乾癬治療効果の経過観察及び早期の予測方法並びにそれらに使用するキット

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009112502A1 (en) * 2008-03-13 2009-09-17 Biotest Ag Agent for treating disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, Vol 102, Pages 8466-8471(2005)*

Also Published As

Publication number Publication date
BR112012012911A8 (pt) 2018-02-27
EP2470902B1 (en) 2017-07-19
IL219956B (en) 2019-07-31
RU2598719C2 (ru) 2016-09-27
KR20120102733A (ko) 2012-09-18
SG181117A1 (en) 2012-07-30
ZA201204845B (en) 2016-06-29
NZ600889A (en) 2015-09-25
GB0920944D0 (en) 2010-01-13
EP2470902A1 (en) 2012-07-04
RU2012127378A (ru) 2014-01-10
MX2012006199A (es) 2012-06-19
JP5959438B2 (ja) 2016-08-02
CN102687010B (zh) 2016-06-15
SG10201407938TA (en) 2015-01-29
US20130004513A1 (en) 2013-01-03
AU2010323045A1 (en) 2012-07-19
AU2010323045B2 (en) 2015-09-24
CN102687010A (zh) 2012-09-19
IL219956A0 (en) 2012-07-31
CA2781836A1 (en) 2011-06-03
US9995733B2 (en) 2018-06-12
JP2013511996A (ja) 2013-04-11
BR112012012911A2 (pt) 2016-10-25
WO2011064407A1 (en) 2011-06-03
ES2643640T3 (es) 2017-11-23
MX347247B (es) 2017-04-17

Similar Documents

Publication Publication Date Title
KR101872746B1 (ko) 질병 치료용 제제
JP7061235B2 (ja) 抗ｃｌｄ１８ａ２ナノ抗体及びその応用
KR102363742B1 (ko) Cd19에 대한 인간화 항원-결합 도메인 및 사용 방법
US8389016B2 (en) Use of a CD28 binding substance for making a pharmaceutical composition
RU2741105C2 (ru) Антитела и химерные антигенные рецепторы, специфичные к cd19
TWI718118B (zh) 針對ｒｏｒ１之特異性抗體及嵌合抗原受體
JP6867955B2 (ja) 抗ｏｘ４０抗体及びその使用方法
JP2021184731A (ja) Ｃｄ１２７に対する抗体
KR20210019993A (ko) Τ 세포 수용체 및 이를 발현하는 조작된 세포
CN116589581A (zh) Ilt结合剂和其使用方法
CN117903307A (zh) Bcma结合分子及其使用方法
JP6896057B2 (ja) 抗原結合分子及びその使用方法
JP2025090566A (ja) ガンマデルタｔ細胞を阻害する、または活性化させる方法
CN113544144A (zh) 变体cd80融合蛋白和相关构建体的方法和用途
KR102869563B1 (ko) 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
EP3072527A1 (en) Immunosuppressant
WO2024090458A1 (ja) 抑制型ｋｉｒに対するアゴニストを用いた免疫拒絶の回避方法
US20230265185A1 (en) Anti-cd22 single domain antibodies and therapeutic constructs
WO2025225645A1 (ja) Ｎｋｇ２ａアゴニストを用いた免疫拒絶の回避方法
TW202521577A (zh) 抗ｏｘ４０ｌ抗體以及其用途
TW202540189A (zh) 在組合療法中能夠結合ｏｘ４０之抗體
JP2022515226A (ja) 検出・処理の構成と方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210626

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210626